Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
9 hedge funds and large institutions have $9.23M invested in Celyad Oncology SA American Depositary Shares in 2020 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
13% more funds holding
Funds holding: 8 → 9 (+1)
38% less capital invested
Capital invested by funds: $15M → $9.23M (-$5.77M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$101K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.14K |
| 3 |
JP Morgan Chase
New York
|
+$39 |
| 4 |
RCA
Ranch Capital Advisors
Sarasota,
Florida
|
+$39 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$11.7M |
| 2 |
Morgan Stanley
New York
|
-$75.6K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$9.76K |
| 4 |
Millennium Management
New York
|
-$8.44K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Victory Capital Management
San Antonio,
Texas
| $8.52M | -$11.7M | -1,200,976 | -60% |
|
|
2
Morgan Stanley
New York
| $343K | -$75.6K | -7,748 | -19% |
|
|
3
Millennium Management
New York
| $175K | -$8.44K | -864 | -5% |
|
|
4
Renaissance Technologies
New York
| $110K | +$101K | +10,300 | New |
|
|
5
Wells Fargo
San Francisco,
California
| $63K | -$9.76K | -1,000 | -14% |
|
|
6
UBS Group
Zurich,
Switzerland
| $17K | +$5.14K | +527 | +48% |
|
7
Bank of Montreal
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
8
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$4K | -500 | Closed |
|
|
9
JP Morgan Chase
New York
| – | +$39 | +4 | New |
|
|
RCA
10
Ranch Capital Advisors
Sarasota,
Florida
| – | +$39 | +4 | New |
|
CYAD Hedge Fund Activity: Q2 2020 in Review
9 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q2 2020, worth a combined $9.23M — down 38% from $15M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CYAD positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $101K. The largest seller was Victory Capital Management, cutting an estimated $11.7M.
- 9 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q2 2020, up from 8 in Q1 2020.
- Funds reported $9.23M of Celyad Oncology SA American Depositary Shares stock for Q2 2020, down 38% quarter-over-quarter.
- 3 funds opened new Celyad Oncology SA American Depositary Shares positions in Q2 2020 and 2 closed out, a net change of +1 holder.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q2 2020 was Renaissance Technologies, an estimated $101K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q2 2020 was Victory Capital Management, an estimated $11.7M sold.
Based on aggregated 13F filings for Q2 2020.